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Summary 53 
In 2001, the World Health Assembly (WHA) passed the landmark WHA 54.19 resolution for 54 
global scale up of mass administration of anthelminthic drugs for morbidity control of 55 
schistosomiasis and soil-transmitted helminthiasis (STH), which affect over 1.5 billion of the 56 
world’s poorest people. Since then, over a decade of research and experience has yielded critical 57 
new knowledge on the control and elimination of these helminthiases. However, the global 58 
strategy has remained largely unchanged since the original 2001 WHA resolution and associated 59 
World Health Organization (WHO) guidelines on preventive chemotherapy. Here, we highlight 60 
recent advances that, taken together, support a call to revise the global strategy and guidelines for 61 
preventive chemotherapy and complementary interventions against schistosomiasis and STH. 62 
This includes the development of guidance that is specific to goals of “morbidity control” and 63 
“elimination of transmission.” We quantify the result of forgoing this opportunity by computing 64 
the yearly disease burden, mortality, and lost economic productivity associated with maintaining 65 
status quo. Without change, we estimate that the population of sub-Saharan Africa will likely 66 
lose 2.3 million disability-adjusted life years and US$3.5 billion of economic productivity every 67 
year, which is comparable to recent acute epidemics, including the 2014 Ebola and 2015 Zika 68 
epidemics. We propose that the time is now to strengthen the global strategy to address the 69 
substantial disease burden of schistosomiasis and STH.  70 
 71 
 72 
 73 
 74 
 75 
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Personal View 76 
Introduction  77 
Over 15 years ago, the World Health Assembly (WHA) passed the landmark WHA 54.19 78 
resolution to address the 1.5 billion people affected by schistosomiasis and soil-transmitted 79 
helminthiasis (STH; including ascariasis, hookworm disease, and trichuriasis).1,2 The WHO 80 
subsequently created a Department of Neglected Tropical Diseases (NTDs), and produced 81 
guidelines that set a new paradigm for a public health approach against many NTDs, including 82 
schistosomiasis and STH, through a strategy of preventive chemotherapy (via ‘mass drug 83 
administration’).3 This strategy involves large-scale, periodic (e.g., yearly) empiric treatment of 84 
entire populations and typically focuses on groups assumed to have the greatest disease 85 
morbidity, such as school-aged children (ages 5-15 years) for schistosomiasis and pre-school and 86 
school-aged children (ages 1-15 years) for STH.3,4 These helminthiases are characterized by 87 
mostly chronic, often insidious helminth-specific sequelae ranging from mild to severe 88 
morbidities. These include anaemia, chronic abdominal pain, and malnutrition, and also more 89 
rare and serious complications including bladder cancer, hepatosplenomegaly, and death for 90 
schistosomiasis and small bowel obstruction and rectal prolapse for STH. 91 
Today, under the auspices of the WHO Department of NTDs, catalyzed by the 2012 92 
London Declaration for NTDs, and with large-scale support from governments, pharmaceutical 93 
companies, and NGOs, preventive chemotherapy programmes have achieved impressive gains. 94 
In 2015 alone, these programmes delivered treatment to 65 million people using praziquantel 95 
(against schistosomiasis) and 565 million people using albendazole or mebendazole (against 96 
STH) throughout Africa, Asia, Latin America, and the Middle East.5,6 Over this period, there 97 
have been corresponding reductions in the number of infections and global disease burden 98 
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estimates.1,2,7 This strategy of “morbidity control” has defined a goal of “eliminating helminths 99 
as a public health problem.” For STH, this is defined as <1% moderate-to-heavy intensity 100 
infection prevalence in at risk populations, as determined by egg counts on microscopic 101 
examination, and for schistosomiasis, the goal has been expressed as <1% heavy-intensity 102 
infections based on egg counts in stools or urine. 103 
While this commendable morbidity control strategy has certainly led to success, mainly 104 
by averting long-term sequelae in school-aged children, the reinfection rate has been high in 105 
most settings.8,9 Unfortunately, even countries that have successfully implemented the 106 
recommended preventive chemotherapy strategy for schistosomiasis and STH—i.e., repeated 107 
treatment of school-aged children at WHO-recommended ≥75% coverage—have met challenges 108 
in achieving optimal morbidity control or the more ambitious goal of transmission 109 
elimination.8,10,11 This finding is consistent with estimates by the Global Burden of Disease 110 
(GBD) study and others that have documented how progress has lagged behind for 111 
schistosomiasis and STH relative to many other NTDs.12 To address this challenge, in light of 112 
the past decade of data and experience from the field, we re-visit the global strategy for 113 
preventive chemotherapy and complementary interventions against schistosomiasis and STH. 114 
Preventive chemotherapy 115 
As the post-2020 agenda for NTDs is considered, there is growing interest in improving the 116 
morbidity control strategy, and when appropriate, shifting towards a more ambitious goal of 117 
“elimination of transmission,” which is defined as interruption of transmission. The critical, 118 
policy-relevant question to be asked is how we can leverage new evidence to strengthen current 119 
strategies and guidelines for preventive chemotherapy to achieve these goals (see Panel 1). The 120 
current strategy of morbidity control emphasises treatment of school-aged children alone (with 121 
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extension to preschool-aged children for STH); however, adolescents and adults (15 years and 122 
older; including pregnant women) and younger children (<5 years) in the case of schistosomiasis, 123 
are often infected and are not rigorously addressed in the current global strategy or in 124 
parasitological monitoring.3,4,13 If left untreated, these groups can serve as a “hidden reservoir” 125 
and potential source of reinfection for all age groups. Modelling studies indicate that expanding 126 
treatment from school-aged children alone to entire communities could substantially reduce 127 
reinfection across all age groups, and avert accumulated morbidity in these populations, 128 
especially schistosomiasis-related chronic sequelae in preschool-aged children.10,13-16 The 129 
relative advantage of community-based treatment has been further supported by a recent 130 
systematic review and meta-analysis of observational studies.17 Furthermore, expanded 131 
community-wide treatment can be highly cost-effective because of this averted morbidity, even 132 
if transmission is not eliminated.10,18 To achieve community-wide coverage, countries could 133 
utilize distribution networks from other community-based health platforms for feasibility and 134 
cost-efficiency, including integration with vaccination programmes, Demographic and Health 135 
Surveys (DHS), or through continued use of lymphatic filariasis or onchocerciasis drug 136 
distributors who have delivered community-wide anthelminthics (e.g., ivermectin, albendazole) 137 
at scale.19,20 138 
Guidelines currently provide “prevalence thresholds”, above which a preventive 139 
chemotherapy strategy is recommended, but given recent experience these may be too restrictive 140 
to achieve optimal averted disability and cost-effectiveness even under a goal of morbidity 141 
control. These prevalence thresholds are based on expert opinion and a historically more limited 142 
drug supply, and have remained largely unchanged for over a decade.3,4 While these thresholds 143 
have guided efforts in preventive chemotherapy, analysis of new data suggest they can be 144 
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improved by considering transmission dynamics and health economics.10,18 Notably, a recent 145 
study that rigorously assessed these prevalence thresholds found them to often be too restrictive 146 
on the basis of morbidity control (measured in disability-adjusted life years (DALYs)) and cost-147 
effectiveness, especially for schistosomiasis.18 For example, annual school-based treatment of 148 
schistosomiasis was cost-effective at 5% prevalence rather than the currently recommended 50% 149 
prevalence, and new prevalence thresholds were defined for community-wide coverage for both 150 
sets of helminthiases.18 Importantly, while expanded treatment would have great potential to 151 
avert disease morbidity, reduce overall reinfection, and prevent chronic sequelae in young 152 
children, the potential emergence of drug resistance from increased treatment pressure is a 153 
concern. Therefore, rigorous methods to monitor drug efficacy will be essential, although 154 
community-wide treatment at 75% coverage still falls under the best practices according to 155 
conservative estimates from veterinary literature.21 This concern can further be addressed by a 156 
longer-term but necessary research and development agenda to create improved drug regimens 157 
with greater efficacies against schistosomiasis and STH (particularly trichuriasis), where drug 158 
efficacy may be lower than expected, or even anthelminthic vaccines to prevent reinfection.22-24 159 
New diagnostics for helminths (e.g., point-of-care circulating cathodic antigen urine cassette test 160 
for Schistosoma mansoni) can also be applied to guide new treatment thresholds.25 161 
Re-examination of the preventive chemotherapy strategy should also consider recent 162 
evidence from the Cochrane Collaboration and Campbell Collaboration systematic reviews and 163 
meta-analyses of trial data that suggests limited benefit of school-based preventive chemotherapy 164 
for STH, although should be considered within the limitations of the data and substantial debate 165 
surrounding potential methodological challenges (see Appendix).26-30 For example, studies may 166 
be underpowered to detect a meaningful effect and relevant health outcomes may not be realized 167 
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within the short timeframe of most trials. Furthermore, children may have high rates of 168 
reinfection in school-based programmes that limits improvements to health, but this could be 169 
overcome with community-wide treatment strategies.10,16,17  170 
The updated global strategy for preventive chemotherapy should increase attention to 171 
country-level coordination of integrated programmatic delivery (i.e., giving multiple medicines 172 
in the same programme) that would yield substantial cost-savings and biological synergies within 173 
the constraints of proven feasibility.10,18,31,32 While integrated preventive chemotherapy 174 
guidelines do exist, improving country-level coordination of these programmes would benefit 175 
cost-efficiency.18,33 The prevalence threshold itself is lower for adding another medicine in 176 
addition to an existing treatment programme compared to a standalone programme due to 177 
reduced delivery cost, and since the majority of cost is from delivery and not the drugs 178 
themselves.10,31 For example, programmatic delivery of praziquantel should include albendazole 179 
or mebendazole, as done by the Schistosomiasis Control Initiative, since STH is most often co-180 
endemic and co-administration is safe.32 The integration of these programmes should work 181 
within the constraints of the drug supply and the relevant ecological zone (e.g., national, sub-182 
national, community) that addresses the focal nature of schistosomiasis, which is in contrast with 183 
the more homogenous nature of STH. 184 
Complementary interventions  185 
The global strategy should include water, sanitation, and hygiene (WASH) interventions, 186 
information, education, and communication (IEC) programmes, and focal snail control (for 187 
schistosomiasis), especially when elimination of transmission is the goal. Coordinated guidelines 188 
are needed that define the conditions (e.g., prevalence threshold, programmatic goals) where 189 
each complementary intervention should be implemented alongside preventive chemotherapy 190 
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within the broad framework of local health needs. While WASH programming, IEC, and snail 191 
control are not the focus of current global efforts, growing evidence supports the need for greater 192 
inclusion within the updated strategy, especially where disease dynamics are recalcitrant to 193 
preventive chemotherapy alone or elimination of transmission is the goal.  194 
The implementation of the WHO WASH-NTD global strategy will likely be essential to 195 
eliminate transmission.34 Observational studies have provided evidence for the relationship 196 
between various components of WASH (including improved water, sanitation, and hygiene and 197 
health behavior) and helminth prevalence and mean intensity.35-39 However, the experimental 198 
evidence from trials is mixed, and studies are ongoing to validate the data from observational 199 
studies.37,39-42 Regardless, these programmes are likely to have substantial spillover benefit by 200 
reducing the incidence of other infectious diseases improving country-level cost-effectiveness.39 201 
The importance of snail control in schistosomiasis control and elimination has been 202 
supported by a recent meta-analysis, empirical analyses of historical data and modelling 203 
studies.15,43,44 The inclusion of multiple means of snail control within a coordinated strategy 204 
alongside preventive chemotherapy for schistosomiasis is an important step forward in 205 
eliminating transmission in low endemicity settings and also controlling disease morbidity in 206 
high endemicity settings. 207 
Guidelines for morbidity control versus elimination of transmission  208 
Distinct programmatic guidance is urgently needed that is specific to the different goals of 209 
“morbidity control” or “elimination of transmission,” and is informed by the setting’s local 210 
helminthiases epidemiology and health priorities of the country. The decision on strategy should 211 
further be made on a sub-national basis with consideration of the focal nature of schistosomiasis. 212 
Importantly, disease burden differs considerably among settings, and elimination of transmission 213 
 10 
may not be possible in all locations with existing tools and resources. High-burden settings may 214 
set a near-term goal of morbidity control, while low-burden settings may target elimination of 215 
transmission. In all cases, settings should first aim to achieve effective morbidity control before 216 
expanding to a goal of elimination of transmission. 217 
To achieve this, settings targeting STH for morbidity control should focus on ensuring high 218 
drug coverage in all risk groups, including preschool-aged children and adults. In contrast, 219 
settings with low prevalence may set a goal of eliminating transmission and may prioritise non-220 
drug interventions such as WASH programming, snail control, and intensive surveillance.45 In all 221 
cases, the country’s goals and resource constraints will inform this choice, and distinct strategic 222 
recommendations should be available to reflect these different scenarios. Importantly, 223 
programmatic goals should be established with full country ownership of these programmes, 224 
especially in regions with an improving economy and health systems. In developed countries, 225 
particular attention should be given to “blue marble health” which recognises the sizable 226 
proportion of the global burden of helminthiasis that occurs in the poorer populations of wealthy 227 
countries will require distinct strategies and political support structures.46 228 
The proposed revision to the global strategy may substantially expand the target population 229 
for preventive chemotherapy and resources needed for complementary interventions. In countries 230 
that have yet to achieve the 2020 goal of at least 75% drug coverage of all at-risk populations, 231 
the development of an updated strategy will serve to clarify resource, drug supply, and 232 
programmatic needs to attain the 2020 goal and beyond. In settings that have reached 75% drug 233 
coverage targets, strengthened guidance should provide an evidence-based strategy towards a 234 
more ambitious and well-defined goal of optimal morbidity control or elimination of 235 
transmission without allowing for infection rebound.  236 
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The historic creation of many aspirational targets in global health, including the “3 by 5” 237 
initiative for HIV/AIDS, the Millennium Development Goals (MDGs), and the London 238 
Declaration on NTDs illustrates the potential of setting a higher bar to improve human health. 239 
The inclusion of NTDs as a specific target within the UN Sustainable Development Goals 240 
(SDGs) signifies the role in achieving Universal Health Coverage.47  241 
To quantify the potential gains of strengthening the global strategy for schistosomiasis and 242 
STH, we compare recent evidence-based strategies for preventive chemotherapy relative to the 243 
current global strategy and idealized WHO guidelines. Without change, we estimate that the 244 
population of sub-Saharan Africa will likely lose 2.3 million DALYs and US$ 3.5 billion of 245 
economic productivity every year, which is comparable to the impact of recent acute epidemics, 246 
including the 2014 Ebola and 2015 Zika epidemics combined (see Table 1, Appendix).  247 
Conclusions 248 
With a shared goal of reducing the burden of NTDs on the world’s poorest people, and 249 
following the leadership of WHO Director-General Dr. Margaret Chan and colleagues around 250 
the world in NTDs, we respectfully advocate for revision of the global strategy and associated 251 
WHO guidelines for schistosomiasis and STH to incorporate new knowledge and experience 252 
gained over the last 15 years. If we miss this opportunity, then we fail to do all we can to help the 253 
populations who suffer the greatest burden of helminthiases and other NTDs. 254 
 255 
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 396 
Panel and Tables 397 
Panel 1: Key steps for strengthening the global strategy for schistosomiasis and STH 398 
 
Key step Strength of evidence 
Step 1: Update strategy for preventive chemotherapy  
 Expanded treatment across broader age groups  
(i.e., community-wide treatment) 
Modelling and cost-effectiveness 
studies10,14,18,48 with support from 
systematic review and meta-analysis of 
observational studies17 
 Lower prevalence thresholds for treatment, especially 
for schistosomiasis 
Modelling and cost-effectiveness 
studies18 with support from observational 
studies 
 Formal guidelines for integration of praziquantel and 
benzimidazole programming 
Cost-effectiveness modelling studies 
with support from feasibility 
studies10,18,31,32 
 Validated strategy with trial data Trials underway 
 Rigorous monitoring and evaluation strategies to 
detect emergence of drug resistance 
Statistical models with field validation49 
Step 2: Incorporate complementary interventions in the global strategy 
 Water, sanitation, and hygiene (WASH) 
programming (e.g. community-led total sanitation) 
Systematic review and meta-analysis 
with mixed findings including mostly 
observational studies34-42 
 Information, education, and communication (EIC) 
programmes  
Trial data40 
 Snail control (for Schistosoma spp). Systematic review and meta-analysis 
including mostly observational studies; 
modeling studies15,43 
Step 3: Create distinct guidelines based on epidemiology, programmatic goals, and resource 
constraints  
 Guidelines for a goal of morbidity control versus 
elimination of transmission  
Expert opinion 
 
 399 
  400 
 16 
Table 1: Annual disease burden, mortality, and economic burden of current global strategy, 401 
idealized WHO preventive chemotherapy guidelines, and cost-effective preventive chemotherapy 402 
guidelines for schistosomiasis and STH  403 
Strategy 
Disease burden 
(DALYs) 
Mortality 
(DALYs) 
Economic lossesc  
(2015 US$, thousands) 
No treatment 4,156,306 176,393 6,482,613 
Current global strategya 3,957,325 176,392 6,182,450 
Idealized WHO guidelinesb 3,474,731 159,921 5,462,829 
Cost-effective guidelines18 1,674,551 88,877 2,715,934 
 
   
Cost-effective guidelines18 
relative to: 
Avertable disease 
burden (DALYs) 
Avertable 
mortality 
(DALYs) 
Avertable economic 
lossesc (2015 US$, 
thousands) 
No treatment 2,481,755 87,516 3,766,679 
Current global strategya 2,282,774 87,515 3,466,516 
Idealized WHO guidelinesb 1,800,180 71,044 2,746,895 
a
Estimation based on WHO guidelines with current global coverage for preventive chemotherapy.
 404 
b
Estimation based on WHO guidelines with 75% coverage and uses school-based preventive chemotherapy 405 
programmes, except for inclusion of preschool-aged children in STH treatment. This reflects the stated priority 406 
within guidelines, the current global strategy, and empirical coverage estimated amongst different age groups. 407 
However, WHO guidelines do recommend treatment of women of childbearing age for STH, and treatment in entire 408 
communities under some circumstances above 50% prevalence for schistosomiasis, although coverage remains 409 
minimal in these groups. 410 
c
Economic losses are estimated as the product of disability (DALYs) and country GDP per capita (see Appendix). 411 
Note: Results are annualized over a 5-year simulation and are intended to give a broad estimate of the magnitude of 412 
avertable health and economic loss. Methodological details, limitations, and discussions of uncertainty are provided 413 
in the Appendix. 414 
 415 
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